Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00355576 · ClinicalTrials.gov registry record · Phase 2
Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT00355576 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 86 participants.
The verdict
NCT00355576, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
The objective of this study is to compare two combinations of drugs, minocycline and creatine or celecoxib and creatine, in a phase II trial designed to determine which combination is more effective for ALS.
Interventions
- DRUG Celecoxib
- DRUG Minocycline
- DRUG Creatine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00355576
The ClinicalTrials.gov registry entry for NCT00355576 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Celecoxib is the first listed.
NCT00355576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00355576 about?
NCT00355576 is a clinical study titled "Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis". The objective of this study is to compare two combinations of drugs, minocycline and creatine or celecoxib and creatine, in a phase II trial designed to determine which combination is more effective for ALS.
What is the current status of trial NCT00355576?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2006-07. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00355576?
The interventions under investigation include: Celecoxib (DRUG), Minocycline (DRUG), Creatine (DRUG).
Who is sponsoring clinical trial NCT00355576?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.